GSK has agreed to pay $2.3 billion to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer.

GSK (LSE: GSK) has settled 93% of Zantac (ranitidine) product liability cases in the USA, agreeing to pay up to $2.2 billion ...

The predicted rise in forecourt prices comes as the amount paid by drivers for petrol has fallen by 15.5p since the start of ...

Tens of thousands of Americans are in line to share $2.2bn (£1.7bn) after GSK agreed a settlement over claims its indigestion drug caused cancers. The British drug giant has agreed to pay up to $2.2bn ...

This week, we take a look at the damage that’s been caused so far by Hurricane Milton in the US, provide an update on the Wagatha Christie case, outline the latest allegations against Google and how ...

Tesla’s sales in China increased by 19.2% in September, totaling over 72,000 electric vehicles sold, its best performance of ...

Pfizer fell amid doubts about an activist investor's plan to overhaul the dormant big pharma company. Hours after former Chief Executive Ian Read and ex-Chief Financial Officer Frank D'Amelio said ...

A spokesman for GSK said: "We’re very confident in our position and continue to vigorously defend ourselves based on the facts and science ... its gastrointestinal drug Zantac caused cancer.

The Marshall Project recently investigated how faulty drug tests at hospitals lead to pregnant women being reported to ...

As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and ...

saved from steeper losses as GSK surged nearly 7% on news that the pharma giant had reached a $2.2 billion deal to settle ...

A Stocks and Shares ISA is a Foolish favourite as investment vehicles go. Our writer details two picks she’d buy for hers to ...